AC-203 clinical trial enrollment starts for EBS patients

AC-203 clinical trial enrollment starts for EBS patients

A Phase 2/3 clinical trial testing AC-203 (diacerein 1% ointment) in people with epidermolysis bullosa simplex (EBS) is recruiting participants. The trial, EBShield (NCT06073132), seeks to enroll approximately 80 people ages 6 months and older with localized, severe, or intermediate EBS. To be eligible for participation, patients must have EBS-related wounds on at least 3% of their total body surface area, not counting the palms of the hands or …